Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Dermatomyositis is a rare autoimmune inflammatory myopathy characterized by muscle weakness and distinctive skin manifestations. According to Christina Thymalil et al. (2024), its global incidence ranges from 1 to 10 cases per million people, with an estimated prevalence of 5 to 20 cases per 100,000 people. As per the dermatomyositis epidemiology forecast by Expert Market Research, disease prevalence remains an important indicator of the affected population.

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Dermatomyositis – Number of Cases by Year

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Dermatomyositis Epidemiology Forecast Report Coverage

Expert Market Research's “Dermatomyositis Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of dermatomyositis. It projects the future incidence and prevalence rates of dermatomyositis cases across various populations. The study covers age, gender, and type as major determinants of the dermatomyositis population. The report highlights patterns in the prevalence of dermatomyositis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of dermatomyositis in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Dermatomyositis Understanding: Disease Overview

Dermatomyositis is a rare, acquired inflammatory disease characterized by muscle weakness and distinctive skin rashes. It is an autoimmune condition in which the immune system mistakenly attacks the body's own tissues, causing inflammation that can affect skeletal muscles and the skin. Common manifestations include weakness in muscles close to the trunk, a violet or reddish rash around the eyelids, and skin changes over the knuckles. The disease can also affect the lungs, joints, and swallowing muscles. Clinical presentations include adult-onset and juvenile dermatomyositis, with some cases associated with underlying malignancy or interstitial lung disease. Idiopathic inflammatory myopathy is a related clinical term that encompasses dermatomyositis and other inflammatory muscle disorders.

Key Report Insights

Parameter

Insight

Largest Patient Pool

United States

Fastest Growing Region

India

High-Risk Population

Females and individuals in childhood or middle-to-late adulthood

Key Diagnostic Method

Clinical assessment supported by laboratory and specialized testing

Major Risk Factor

Dermatomyositis is an autoimmune inflammatory disease. Adult-onset disease may be associated with malignancy, while genetic and environmental contributions remain under investigation

Major gap in the market

Diagnostic delays and limited disease-specific treatment options

Dermatomyositis Epidemiology Perspective

The dermatomyositis epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the dermatomyositis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for dermatomyositis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

According to Christina Thymalil et al. (2024), global dermatomyositis prevalence is estimated at 5-20 cases per 100,000 people. Healio reports an adult prevalence of 21.4 per 100,000 in the United States. These estimates reflect different populations and should be interpreted in context.

Gender-Specific Cases of the Disease

As reported by Christina Thymalil et al. (2024), dermatomyositis is approximately twice as common in females as in males. Patrick Gordon et al. (2026) also reported an 84% higher incidence of dermatomyositis among females in an England-based population cohort.

Age-Specific Cases of the Disease

According to Wayan Julita K. Putri (2023), dermatomyositis has a bimodal age distribution, with peaks at 5-14 and 45-64 years. Juvenile dermatomyositis commonly begins between 4 and 10 years, as reported by Jung Woo Rhim (2021).

Ethnicity-Wise Cases of the Disease

According to Christina Thymalil et al. (2024), higher prevalence has been reported among African American adults. Patrick Gordon et al. (2026) found higher dermatomyositis incidence among South Asian and Black populations than among White populations in England.

Mortality and Survival Analysis of the Disease

The supplied epidemiological information does not quantify mortality or survival rates. Population-level assessment should consider long-term outcomes alongside age at onset, sex, ethnicity, and disease-associated complications, without inferring mortality estimates from incidence or prevalence figures.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

Classic Dermatomyositis

A major form of dermatomyositis characterized by typical skin rashes and symmetrical proximal muscle weakness.

Clinically Amyopathic Dermatomyositis (CADM)

A recognized subtype characterized by typical skin manifestations without clinically apparent muscle weakness.

Hypomyopathic Dermatomyositis

A less apparent form involving characteristic skin manifestations and subtle or subclinical muscle involvement.

Postmyopathic Dermatomyositis (PmDM)

A less common form in which skin symptoms persist after muscle inflammation has resolved or become well controlled.

Juvenile Dermatomyositis (JDM)

A distinct form affecting children and adolescents, often associated with muscle weakness, vascular manifestations, and calcinosis.

Malignancy-Associated Dermatomyositis

A clinically important subtype associated with underlying malignancy, particularly in adults, requiring consideration of cancer-related associations.

Dermatomyositis – Number of Cases by Country

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Country-wise Dermatomyositis Epidemiology

The dermatomyositis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

According to Healio, adult dermatomyositis incidence is 15.2 cases per million person-years, with a prevalence of 21.4 cases per 100,000 people. Jung Woo Rhim (2021) reported juvenile dermatomyositis incidence of approximately 3 cases per million children annually.

Germany

In Germany, dermatomyositis prevalence may be influenced by improved disease recognition, access to specialist care, and more effective identification of autoimmune inflammatory myopathies among adult and pediatric populations.

France

Increased awareness of autoimmune disorders and improved diagnostic evaluation may contribute to the identification of more dermatomyositis cases, including patients with varied age-related presentations, in France.

Italy

In Italy, greater recognition of dermatomyositis among older adults and children, alongside improved access to specialist assessment, may support the identification of previously unrecognized cases.

Spain

Improvements in the recognition and diagnosis of rare autoimmune conditions may contribute to identifying dermatomyositis cases across different age groups and reducing underdiagnosis in Spain.

United Kingdom

According to Jung Woo Rhim (2021), juvenile dermatomyositis incidence is approximately 3.2 cases per million children annually. Patrick Gordon et al. (2026) reported higher dermatomyositis incidence among females and among South Asian and Black populations than among males and White populations in England.

Japan

As reported by Hinako Suzuki et al. (2023), the prevalence of polymyositis/dermatomyositis ranges from 10 to 13 cases per 100,000 people. This estimate covers the combined disease category rather than dermatomyositis alone.

India

According to Dibyasundar Mahanta et al. (2024), the reported incidence of dermatomyositis in Indian adults is 2.8-3 cases per 100,000 adults. This estimate should be interpreted according to the measure and population specified in the source.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

Across the United States, Germany, France, Italy, Spain, the United Kingdom, Japan, and India, dermatomyositis presents opportunities to improve early diagnosis, disease monitoring, and access to effective treatment. Its variable presentation across muscle, skin, and other organs can delay recognition and complicate disease management. A major unmet need is the development of therapies that provide sustained disease control while reducing reliance on long-term corticosteroids. Additional opportunities include improving access to specialist assessment, myositis antibody testing, and screening for associated complications, including interstitial lung disease and malignancy where clinically indicated.

Dermatomyositis: Treatment Overview

Dermatomyositis treatment aims to control inflammation, improve muscle strength, manage skin symptoms, and prevent organ complications. Systemic corticosteroids, such as prednisone, are commonly used as initial therapy, while steroid-sparing immunosuppressants, including methotrexate, azathioprine, or mycophenolate mofetil, may help maintain disease control and reduce long-term corticosteroid exposure. Intravenous immunoglobulin may be used in selected patients, particularly those with severe muscle weakness or inadequate response to conventional treatment. Topical therapies, sun protection, and antimalarial medicines may help manage skin manifestations. Physical therapy and regular monitoring support functional recovery and identify complications. Immunomodulatory therapy is an important treatment approach, with selection guided by disease severity and organ involvement.

Key Questions Answered

  • What is the current and projected burden of dermatomyositis across the 8 major markets?
  • Which countries across the 8 major markets account for the highest dermatomyositis patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of dermatomyositis across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of dermatomyositis across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of dermatomyositis across the 8 major markets?
  • How do major comorbidities and risk factors influence dermatomyositis epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of dermatomyositis across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the dermatomyositis landscape across the 8 major markets?
  • Which therapeutic areas linked to dermatomyositis are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the dermatomyositis epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on dermatomyositis epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for dermatomyositis across the 8 major markets?

Scope of the Dermatomyositis Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of dermatomyositis based on several factors.
  • Dermatomyositis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The dermatomyositis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Dermatomyositis Pipeline Analysis

Intravenous Immunoglobulin Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us